Consumer Defensive
United-Guardian, Inc.(UG)
Live Price
Offline$7.02
+0.29% today
1Y Change
-14.49%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- $30.00M
- Revenue Growth
- -13.4%
- EPS Growth
- -35.2%
- Dividend Yield
- 6.9%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
United-Guardian, Inc. (UG) is a Consumer Defensive stock with a market cap of $30.00M and listed on NASDAQ. The stock last traded around $7.02 and down 14.5% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of -13.4%, EPS growth of -35.2%, a dividend yield of 6.9%. What stands out right now is revenue -13.4%, EPS -35.2%, free cash flow -37.1% with operating margin 21.3% and ROIC 15.2%. The dividend matters to the case here, with a current yield around 6.9%. Valuation is more restrained than many high-expectation growth names at P/E 15.9 and price/sales 3.2. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines UG price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Consumer Defensive peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-13.4% vs +1.7% peer median
Operating Margin
Above sector median
+21.3% vs +6.6% peer median
P/E
Near sector median
15.9 vs 14.0 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -13.4% and EPS is at -35.2%, with operating margin around 21.3%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 6.9%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.2% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | +4.3% | +4.2% | +4.3% |
2026 Mar 27, 2026 | โ | +1.2% | +1.1% | +6.3% |
2025 Nov 6, 2025 | โ | -3.2% | -5.9% | -8.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
UG
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
UG Max Drawdown
-41.34%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for UG and SPY.
Company Overview
United-Guardian, Inc.
NASDAQ Global Market
United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary specialty industrial products in the United States and internationally. The company offers cosmetic ingredients, including LUBRAJEL line of water-based moisturizing and lubricating gel formulations; LUBRAJEL NATURAL consisting of natural ingredients for cosmetic use; LUBRAJEL MARINE; LUBRASIL II SB, a special formulation of LUBRAJEL in which silicone oil is incorporated into a LUBRAJEL base; LUBRAJEL II XD; B-122, a powdered lubricant that is used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; KLENSOFT, a surfactant, which is used in shampoos, shower gels, makeup removers, and other cosmetic formulations; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, cleansers, and other cosmetics. Its medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL LC and LUBRAJEL FA that are LUBRAJEL formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. The company's pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial product to treat infections in the urinary bladder, and localized infections in the peritoneum, as well as eye, ear, nose and throat, and sinuses. Its industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. The company also conducts research and development primarily related to the development of cosmetic ingredients. It markets its products through marketing partners, distributors, and wholesalers. The company was founded in 1942 and is based in Hauppauge, New York.
- Leadership
- Donna Vigilante
- IPO Date
- Mar 17, 1980
- Employees
- 24
- Street Address
- 230 Marcus Boulevard
- Mailing
- Hauppauge, NY, 11788
- Region
- Hauppauge, NY, US
- Reporting Currency
- USD
- Investor Line
- 631 273 0900
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 15.9
- EV/EBITDA
- 13.7
- Price/Sales
- 3.2
- Price/Book
- 3.0
Growth
- Revenue
- -13.4%
- EPS
- -35.2%
- Free Cash Flow
- -37.1%
Profitability
- Gross Margin
- 47.7%
- Operating Margin
- 21.3%
- Net Margin
- 20.0%
- ROE
- 19.1%
- ROIC
- 15.2%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 7.31
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.